GlassScriptPhysician profile
Kelly R Shephard
NPI 1528723814
$3,711.39
in general payments reported to CMS, 2019-2025
20 companies · $820 in 2025
The $820 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,502 · 2023: $499 · 2024: $890 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,103 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,102.83 |
| Education | $106.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $692.45 | 2022-2025 | Ingrezza |
| Abbvie INC. | $593.77 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $440.47 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $401.42 | 2023-2025 | Austedo Xr, Austedo Xr |
| Tris Pharma INC | $296.30 | 2022-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $251.74 | 2024-2025 | Qelbree |
| Lundbeck LLC | $242.75 | 2022-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $167.99 | 2022 | |
| Bausch Health US, LLC | $124.94 | 2022-2025 | Wellbutrin, Aplenzin |
| Almatica Pharma LLC | $94.66 | 2023-2024 | Loreev Xr, Gralise |
| Axsome Therapeutics, INC. | $91.64 | 2023-2024 | Sunosi, Auvelity |
| Collegium Pharmaceutical, INC. | $65.36 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $56.47 | 2022-2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $49.17 | 2024-2025 | Fanapt |
| Neos Therapeutics, LP | $33.69 | 2024-2025 | Adzenys Xr-Odt |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $27.26 | 2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $25.86 | 2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $24.82 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.80 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Shephard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.